if a patient does not respond appropriately to a macrolide, a fluoroquinolone should be added to the treatment regimen
patients with significant Mycoplasma hepatitis may be considered for a renally excreted fluoroquinolone rather than a hepatic metabolised macrolide, although either class can cause hepatotoxicity, although antibiotic induced fulminant hepatic failure is very rare
they are amongst the smallest of bacterial species and are typically 0.1 micron in diameter
can survive without oxygen
mycoplasma pneumoniae
a common cause of "atypical pneumonia" acquired in the community accounting for ~40% of cases, particularly in children and the elderly
also causes tracheobronchitis (esp. children), wheeze, headache, myalgias and URTI
~25% also develop extrapulmonary symptoms such as autoimmune responses, central nervous system complications, and dermatological disorders
20% develop abnormal LFTs, and 2-5% of cases present as hepatitis in which case average C reactive protein (CRP) is 140 instead of 70 for M.pneum without hepatitis 1)
exclusively parasitizes the respiratory tract epithelium of humans
has never been isolated as a free-living organism due to its dependence upon the host for survival thus spread is via droplets to those in close and prolonged contact such as households, schools, nursing homes.
treatment is usually single dose of azithromycin as well as partners being treated and then re-tested after 1 month to ensure clearance
resistance to azithromycin is developing rapidly since ~2007 when the 1st cases in Australia were found to be resistant, in 2017, 50-80% had become resistant!